Schedule III Is Finally Moving: What the 2026 Rescheduling Actually Changed
CRC Manufacturing · April 30, 2026 · 3 min read
After years of procedural drift, federal rescheduling produced an actual order in April 2026 — but a narrower one than most headlines suggested. Here is what changed, what did not, and what it means for a California brand running adult-use SKUs.
What the April 23 order did
On April 23, 2026, the Justice Department and DEA placed two categories of marijuana products into Schedule III of the Controlled Substances Act, effective immediately. The first is FDA-approved marijuana products. The second is marijuana products regulated under a qualifying state medical license.
Everything else — including California adult-use product — remains in Schedule I for now. That is the single most important sentence in the order for most operators. The move is real, it is in force, and it does not cover the recreational market that makes up the overwhelming majority of licensed California sales.
The broader proceeding is still open
Alongside the April order, DEA withdrew its earlier hearing notices and set an expedited hearing on broader rescheduling. That hearing ran from June 29 to July 15, 2026. The administrative law judge's recommendation is expected in late 2026, and the DEA Administrator makes the final decision after that.
Separately, a challenge to the April order is pending in the D.C. Circuit. So there are two live tracks: an administrative one that could widen Schedule III treatment, and a judicial one that could disturb what has already been issued. Neither is resolved, and neither has a date certain.
The 280E question
Section 280E of the tax code denies ordinary business deductions to any trade or business trafficking in Schedule I or II controlled substances. Moving a product to Schedule III removes it from that clause, which is why rescheduling has always been discussed as a tax event more than a legal one.
The IRS has signaled that 280E relief would likely apply to medical-only operations under the April order. It has not extended that reading to adult-use operators, because the adult-use product itself has not been rescheduled. A California manufacturer producing adult-use goods should assume 280E still applies to its return until broader rescheduling is finalized.
Second-order effects worth tracking
Beyond taxes, Schedule III status tends to loosen three things over time: cost of capital, banking access, and research. Lenders and payment processors price legal risk, and a partial reschedule gives their compliance teams something concrete to work with even where the borrower's own products aren't covered.
Research is the quieter change. Schedule III materially lowers the barrier to clinical work, which over a few years shapes what claims a product can make and what formats regulators are comfortable with. That is not a 2026 revenue line, but it is the reason the order matters beyond the medical channel.